Cargando…
Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease
BACKGROUND: Atherosclerotic cardiovascular disease is the leading cause of death and disability in the Western world. OBJECTIVE: To characterise adults with confirmed coronary heart disease (CHD) and primary heterozygous familial or non-familial hypercholesterolaemia or mixed dyslipidaemia who recei...
Autores principales: | Steffens, Daniel, Bramlage, Peter, Müller, Julia, Dorn, Cornelia, Paar, W Dieter, Scheeff, Celine, Kasner, Mario, Rauch-Kröhnert, U |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130756/ https://www.ncbi.nlm.nih.gov/pubmed/34001653 http://dx.doi.org/10.1136/openhrt-2021-001572 |
Ejemplares similares
-
Lower coronary plaque burden in patients with HIV presenting with acute coronary syndrome
por: O'Dwyer, E J, et al.
Publicado: (2016) -
Lipid lowering with inclisiran: a real-world single-centre experience
por: Padam, Pritpal, et al.
Publicado: (2022) -
Outcomes of patients with spontaneous coronary artery dissection
por: McGrath-Cadell, Lucy, et al.
Publicado: (2016) -
Risks and benefits of percutaneous coronary intervention in spontaneous coronary artery dissection
por: Kotecha, Deevia, et al.
Publicado: (2021) -
Long-term survival after coronary bypass surgery and percutaneous coronary intervention
por: Mølstad, Per, et al.
Publicado: (2016)